Efficacy and safety of sacral nerve root magnetic stimulation combined with solifenacin in female patients with overactive bladder.

IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL American journal of translational research Pub Date : 2025-01-15 eCollection Date: 2025-01-01 DOI:10.62347/EHTT9544
Yan-Qun Dong, Qing Wang, Li Zhang, Ji-Dong Guo, Hui Huang, Jie Wu, Rong-Zhen Tao
{"title":"Efficacy and safety of sacral nerve root magnetic stimulation combined with solifenacin in female patients with overactive bladder.","authors":"Yan-Qun Dong, Qing Wang, Li Zhang, Ji-Dong Guo, Hui Huang, Jie Wu, Rong-Zhen Tao","doi":"10.62347/EHTT9544","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the efficacy and safety of sacral nerve root magnetic stimulation (SNRMS) combined with solifenacin in female patients with overactive bladder (OAB) symptoms.</p><p><strong>Methods: </strong>A total of 183 female patients with OAB symptoms were prospectively randomized into 2 groups. Ninety-two patients in the combination group accepted SNRMS and solifenacin therapy and 91 patients serving as control accepted only solifenacin therapy. The lower urinary tract symptoms, OAB questionnaire (OAB-q) health-related quality of life (HRQoL), symptom bother score, and overactive bladder syndrome score (OABSS) were compared between the two groups at the end of the second, fourth, and eighth weeks.</p><p><strong>Results: </strong>The incidence of lower urinary tract symptoms, including urgency, frequent urination, and incontinence episodes, was significantly lower in the fourth and eighth weeks in patients of the combination treatment group than those in the solifenacin group (<i>P</i> < 0.05). The incidence of drug-related adverse events in the two groups was similar, with no statistically significant difference (<i>P</i> > 0.05). The OAB-q HRQoL score in the combination group was significantly higher than that in the solifenacin group between the fourth and eighth weeks (<i>P</i> < 0.05). Meanwhile, the OAB-q symptom bother score and OABSS were both lower in the combination group than those in the solifenacin group from the fourth to eighth weeks (<i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>The combination therapy of SNRMS and solifenacin demonstrated significant improvements over solifenacin monotherapy in reducing OAB symptoms in female patients, providing a higher QoL without increasing bothersome adverse effects.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 1","pages":"685-692"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826160/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/EHTT9544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to assess the efficacy and safety of sacral nerve root magnetic stimulation (SNRMS) combined with solifenacin in female patients with overactive bladder (OAB) symptoms.

Methods: A total of 183 female patients with OAB symptoms were prospectively randomized into 2 groups. Ninety-two patients in the combination group accepted SNRMS and solifenacin therapy and 91 patients serving as control accepted only solifenacin therapy. The lower urinary tract symptoms, OAB questionnaire (OAB-q) health-related quality of life (HRQoL), symptom bother score, and overactive bladder syndrome score (OABSS) were compared between the two groups at the end of the second, fourth, and eighth weeks.

Results: The incidence of lower urinary tract symptoms, including urgency, frequent urination, and incontinence episodes, was significantly lower in the fourth and eighth weeks in patients of the combination treatment group than those in the solifenacin group (P < 0.05). The incidence of drug-related adverse events in the two groups was similar, with no statistically significant difference (P > 0.05). The OAB-q HRQoL score in the combination group was significantly higher than that in the solifenacin group between the fourth and eighth weeks (P < 0.05). Meanwhile, the OAB-q symptom bother score and OABSS were both lower in the combination group than those in the solifenacin group from the fourth to eighth weeks (P < 0.05).

Conclusions: The combination therapy of SNRMS and solifenacin demonstrated significant improvements over solifenacin monotherapy in reducing OAB symptoms in female patients, providing a higher QoL without increasing bothersome adverse effects.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
American journal of translational research
American journal of translational research ONCOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
552
期刊介绍: Information not localized
期刊最新文献
A new blood draw method in mice. Effect of radiofrequency catheter ablation on cardiac function and quality of life in atrial fibrillation patients. Esophageal bezoar formation: case report and review of the literature. Establishment and evaluation of a rat model of cervical spondylosis with Yin deficiency syndrome. Expression of Serum Ferritin, Human neutrophil lipocalin, Procalcitonin, and inflammatory factors in children with Kawasaki disease and their relationship to coronary artery lesions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1